Jian Pang, MD
Endocrinology, Diabetes & Metabolism · Newnan, GANPI 1558637058
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,410 of the $10,467 with a category attached, or 89.9%. It is spread thinly across 45 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations.
Across 435 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Novo Nordisk$1K
- Abbott$1K
- Lilly USA, LLC$909
- IBSA Pharma Inc.$642
- Xeris Pharmaceuticals, Inc.$600
- plus $5K from 39 others
What the payments were for
- Travel & lodging$8008%
- Food & beverage$9,41090%
- Education$1982%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$731
- MOUNJARO$226
- TARPEYO$133
- VYEPTI$125
- Veozah$125
- GVOKE HYPOPEN$108
- Ozempic$102
How this compares
$10,467 in reported general payments places this provider in the 80th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 113 | $179,880 |
| JardianceEmpagliflozin | 72 | $80,011 |
| FarxigaDapagliflozin Propanediol | 29 | $42,448 |
| TymlosAbaloparatide | 12 | $35,717 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $31,264 |
| TrulicityDulaglutide | 18 | $30,854 |
| KerendiaFinerenone | 21 | $27,271 |
| JanuviaSitagliptin Phosphate | 21 | $25,386 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $18,271 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $16,382 |
| MounjaroTirzepatide | 13 | $13,265 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $10,354 |
| TradjentaLinagliptin | 16 | $8,238 |
| Novolog FlexpenInsulin Aspart | 34 | $6,521 |
| NovologInsulin Aspart | 12 | $5,257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,159 | $185,138125 claims |
| Boehringer IngelheimJardiance, Tradjenta | $311 | $88,24988 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $909 | $44,11931 claims |
| AstraZenecaFarxiga | $281 | $42,44829 claims |
| Radius Health, Inc.Tymlos | $458 | $35,71712 claims |
| BayerKerendia | $404 | $27,27121 claims |
| MerckJanuvia | $52 | $25,38621 claims |
| AbbVieSynthroid | $215 | $3,99138 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $131 | $1,722174 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Newnan
- Sabrina ReneNewnan$20K
- Charles FarmerNewnan$9K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.